Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have earned an average rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $20.43.
LRMR has been the topic of several recent analyst reports. Oppenheimer started coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 price target on the stock. Robert W. Baird assumed coverage on Larimar Therapeutics in a research note on Wednesday, September 4th. They set an “outperform” rating and a $16.00 target price for the company. Wedbush initiated coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price target on the stock. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, HC Wainwright initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $15.00 target price on the stock.
View Our Latest Stock Report on Larimar Therapeutics
Hedge Funds Weigh In On Larimar Therapeutics
Larimar Therapeutics Stock Up 0.6 %
LRMR opened at $8.01 on Thursday. The stock has a market capitalization of $511.05 million, a price-to-earnings ratio of -8.26 and a beta of 0.98. Larimar Therapeutics has a twelve month low of $2.18 and a twelve month high of $13.68. The company has a 50-day simple moving average of $7.32 and a 200 day simple moving average of $7.78.
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Sell-side analysts anticipate that Larimar Therapeutics will post -1.38 EPS for the current fiscal year.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Featured Articles
- Five stocks we like better than Larimar Therapeutics
- What Are Dividend Achievers? An Introduction
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the S&P 500 and How It is Distinct from Other Indexes
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.